

ISLHD HAEMATOLOGY CLINICAL TRIALS

Illawarra Cancer Care Centre

February 2025

ISLHD CANCER CLINICAL TRIALS UNIT

**Illawarra Cancer Care Centre
Wollongong Hospital
Loftus Street
Wollongong NSW 2500**

Ph: 02 4253 4384

Fax: 02 4222 5085

**Email: ISLHD-
CancerClinicalTrials@health.
nsw.gov.au**

Clinical Trials available
through the Illawarra
Shoalhaven Local Health
District can be found on
the ClinTrial Refer App.
Scan the QR code below
to download ClinTrial
Refer.



The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge, development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Multiple Myeloma
- Acute Myeloid Leukaemia
- Diffuse Large B-Cell Lymphoma
- Hodgkin Lymphoma

REFERRAL OR CONSULTATION

To discuss your patient with an ISLHD
Haematology Trials Clinician, please phone
Haematology on 02 4253 4009

ISLHD Haematology Clinical Trials

****CURRENTLY OPEN FOR RECRUITMENT****

Scan the QR Code for more information including eligibility criteria

Multiple Myeloma

ACT16482: Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents compared to isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM).

****Sub-study 06****

Dr Parmar
Cassandra
Jory



CA057-001: A Phase 3, Two-Stage, Randomized, Multi-center, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM).

Dr Parmar
Limna
Chullikkadan
Yohannan
***Satellite site**



MAJESTEC-7: A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy.

Dr Parmar
Amelia Fe-
neck/ Carla
Brown



MonumentAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide.

Dr Parmar
Sam Hughes/
Carla Brown



TCD17710: First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell maturation antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory light chain amyloidosis (RRLCA).

Dr Parmar
Lucy Cable/
Tameika Tu-
baro



LTS17704: International, multi-center, open-label, treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab-based therapy following completion of a phase 1, 2, or 3 parental study.

****Parental studies TCD15484 and IKEMA****

Dr Parmar
Tiffany
Koutsouradis/
Sally Santia-
goo



MAGNETISMM-7: A randomised, 2-Arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stem-cell transplantation.

Dr Cartwright
Kiara Porter



ISLHD Haematology Clinical Trials

****CURRENTLY OPEN FOR RECRUITMENT****

...Multiple Myeloma

TED18162: A first-in-human, open-label, Phase 1 study to evaluate the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of subcutaneous SAR446523, an anti-GPRC5D ADCC-enhanced monoclonal antibody, in participants with relapsed/refractory multiple myeloma.

Dr Parmar
Lucy Cable/
Tameika Tu-
baro



R7945-ONC-22110 (COSTIMM): A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma

Dr Parmar
Lucy Cable/
Tameika Tu-
baro



Acute Myeloid Leukaemia

AML M22/D2: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.

Dr Presgrave
Carla Brown



TCD17796: A Phase 1/Phase 2, randomized, open-label, multi-center study, assessing the safety, tolerability and the preliminary efficacy of SAR443579 administered in combination with azacitidine + venetoclax in adult participants with CD123 expressing newly diagnosed Acute Myeloid Leukemia (ND-AML) that are ineligible for intensive chemotherapy

Dr Presgrave
Lucy Cable/
Tameika
Tubaro



Lymphoma

M22-128: A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab plus Lenalidomide compared to Rituximab plus Gemcitabine and Oxaliplatin in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Dr Presgrave
Danielle Di
Pietro



ALLG HD11: A randomised phase II study of Pembrolizumab and Brentuximab vedotin versus GDP (gemcitabine, dexamethasone and cisplatin), followed by high dose chemotherapy and autologous stem cell transplantation for relapsed/refractory classical Hodgkin Lymphoma

Dr Desai
Cassandra
Jory



ISLHD Haematology Clinical Trials

****CURRENTLY OPEN FOR RECRUITMENT****

For further information regarding these trials at the Illawarra Cancer Care Centre you may also contact the dedicated trial coordinator as listed or email ISLHD-HaematologyTrials@health.nsw.gov.au

<i>Trial Coordinator</i>	<i>Availability</i>	<i>Contact details</i>
Danielle Di Pietro (team leader)	Mon-Fri	02 4255 1415
Tameika Tubaro (CNS2)	Mon-Thurs	02 4222 5230
Kiara Porter	Mon-Fri	02 4222 5276
Carla Brown	Mon-Wed	02 4253 4082
Cassandra Jory	Wed-Fri	02 4253 4173
Tiffany Koutsouradis	Wed-Fri	02 4253 4039
Amelia Feneck	Mon-Wed	02 4225 5227
Lucy Cable	Mon-Thurs	02 4253 4933
Sam Hughes	Mon-Fri	02 4222 5553
Sally Santiagoo	Mon-Fri	02 4255 1495
Limna Chulikkadan Yohannan	Mon-Tue	02 4253 4173

